Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: major Q4 catalysts; Verona’s COPD contender; Alfasigma acquires Intercept; more setbacks for Keytruda/Lenvima combo; and new pressures on China IPOs.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 29 September 2023, including: major Q4 catalysts; Verona Pharma plc’s COPD contender; Alfasigma S.p.A. acquires Intercept Pharmaceuticals, Inc.; more setbacks for Keytruda/Lenvima combo; and new pressures on China IPOs.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Biopharma’s Must-Know Q4 Catalysts" - Scrip, 26 Sep, 2023.)
(Also see "What Verona Needs To Make COPD Drug Ensifentrine A Success" - Scrip, 26 Sep, 2023.)
(Also see "Italy’s Alfasigma Comes Calling After Intercept’s Cruel Summer" - Scrip, 26 Sep, 2023.)
(Also see "Two LEAPs Behind: Merck/Eisai Post Pair Of Failures Of Keytruda/Lenvima Combo" - Scrip, 22 Sep, 2023.)
(Also see "China’s IPO Tightening Adds To Uncertainties Over Biotechs Going Public" - Scrip, 28 Sep, 2023.)